Plan costs increase to unsustainable levels, threatening a plans solvency Pain Point : GLP-1 medications, while effective for diabetes and weight loss, drive up health care costs for employers and their self-funded plans
[DOI] [PubMed] [Google Scholar] 158.Gorgojo-Martnez J.J., Mezquita-Raya P., Carretero-Gmez J., et al
Clinical trials have shown that tirzepatide (Mounjaro, Zepbound) generally leads to greater weight loss compared to semaglutide (Ozempic, Wegovy)
doi: 10.1111/obr.13717, 54
This allows the activation of the gene-promoting migration and invasion of PCa [16]
When fibre is fermented by the trillions of bacteria that live in our intestines, the resultant byproduct, called short chain fatty acids, stimulates the production of GLP-1